Dr. John Cush RheumNow
4 years 5 months ago
Beijing #RA Cohort study compared 102 T2T (CENTRA) vs 271 usual care pt (TARRA) groups for SDAI outcomes at 12 mos. CENTRA had signif lower SDAI than TARRA (2.1 vs 3.4; p<0.001) & more SDAI-defined remission (71% vs 49%; p<0.001) https://t.co/1JBP33eifI https://t.co/RmGny30QAq
Patient TS was a 30 year old woman who had been living with psoriatic arthritis for about 18 months. Her symptoms had started about 6 months after the birth of her first child with mild psoriasis in her scalp but increasing joint pain in her hands, wrists, elbows, knees, and ankles. She had dactylitis in several fingers that caused her extreme pain.
Dr. John Cush RheumNow
4 years 5 months ago
QD Clinic - PsA Lessons from the Clinic
What are the Safe Treatment Options for psoriatics who have HIV?
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/fh00ydSYd3 https://t.co/fpDl2tF4cw
Dr. John Cush RheumNow
4 years 5 months ago
Miss this blog from earlier in the month?
Dr. Eric Ruderman ( @jointMD) weighs in on combined clinics for PsA and its value.
https://t.co/4mdjmetGvF https://t.co/nJJXmk0a0t
Dr. John Cush RheumNow
4 years 5 months ago
ABP 654 is a Ustekinumab (anti-IL-12/23) biosimilar from Amgen - 563 pt, phase 3 trial shown to be equivalent to originator in mod- severe plaque psoriasis (no meaningful differences). ABP 654 is also being developed for Crohns & UC. https://t.co/vDNfMXCWcC
Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.
Dr. John Cush RheumNow
4 years 5 months ago
Italian retrospective of Canakinumab in 80 kids w/ Systemic JIA - 12 moved from anakinra to CAN w/ iinactive dz/CID. 58 pts w/ active SoJIA started CAN - CID in 57% at 6mos, 64% 12 mos; MAS 3/100PY; Nonresp assoc w/ MAS, #Jts, Dz duration https://t.co/2YmkukU7Z2
Inflammatory involvement of the axial skeleton and sacroiliac joints occurs, on average, in 40-50% of patients with psoriatic arthritis (PsA).
When present, axial involvement is a “biomarker” of more severe PsA disease: more severe peripheral joint disease, enthesitis, skin disease, pain, impaired function and quality of life, and work productivity. Thus, it is important to recognize and include in a comprehensive PsA treatment approach.
Dr. John Cush RheumNow
4 years 5 months ago
Open label, RCT compared triple DMARD Rx adding either LEF (MLH) or SSZ (MSH) to MTX+HCQ in 136 RA pts. Both were equally effective (non-inferior), 61.7% & 64.7% patients (p = 0.8) at wk 24. AE were also equal (15 vs 21 AE). https://t.co/cxdeBfo6XA
Dr. John Cush RheumNow
4 years 5 months ago
2 studies from NKF meeting shows gout occurs in 13.5% of CKD on dialysis; and seen in 17-28% of Stg 3,4 CKD pts. CKD w/ Gout has more bone/mineral Dz (40 vs 26%), CHF (21 vs 14%), DJD (17 vs 9%); >1/3 NOT on urate lowering therapy https://t.co/sn40xqxRyg https://t.co/ewb0tpWukw
Dr. John Cush RheumNow
4 years 5 months ago
Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP
The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.
The study set out to investigate whether dietary changes or antioxidant supplementation or 5-10% weight loss could improve disease activity (skin and joint) in patients with PsA.
Dr. John Cush RheumNow
4 years 5 months ago
ICYMI: Copenhagen study of COVID & Rheum disease (AIRD)
▶️ COVID+ AIRD pts have 10x more hospitalizations (7% vs 0.7%)
▶️ Only RTX assoc w/ COVID hosp (adj OR 14.6)
▶️ IgG Abs increased if AIRD pt hospitalized
https://t.co/VtERRZsGb8 https://t.co/ZwdfNJaAS7

